Eli Lilly Acquires Merida Biosciences for $2.88 Billion to Expand into Autoimmune Diseases
Eli Lilly (LLY) has agreed to acquire privately held biotech firm Merida Biosciences in a deal valued up to $2.88 billion, marking its latest move beyond obesity and diabetes treatments toward autoimmune disease research. The acquisition is part of Lilly’s broader strategy to diversify its pipeline after becoming the world's most valuable pharmaceutical company due to blockbuster weight-loss drugs Mounjaro and Zepbound. Merida specializes in developing therapies that target specific autoantibodies responsible for autoimmune conditions, avoiding broad immune suppression seen in traditional treatments. Its lead candidate, MER511, is currently in Phase 1 trials for Graves’ disease and thyroid eye disease. The deal structure includes upfront payments and milestone-based funding tied to clinical progress, limiting Lilly’s financial exposure if the drugs fail. While this acquisition aligns with Lilly's ongoing efforts to expand into immunology through multiple deals in 2026, it is unlikely to impact earnings soon due to the early-stage nature of Merida’s drug candidates. Analysts view the move as a strategic use of capital and an indication that management aims to reduce reliance on its obesity-focused portfolio.
Tickers: $LLY
Topics: Autoimmune diseases Corporate strategy Obesity drugs Pharmaceuticals